Cognizant collaborates with Florence Healthcare to Integrate the Cognizant Shared Investigator Platform.

The Cognizant Life Sciences Business, which is a trusted partner of the World’s top Pharma and biotech companies, and Florence, the electronic investigator site file (eISF) and remote connectivity platform used in 8,500 study sites across 34 countries, have partnered for a joint initiative to enhance collaboration between clinical trial sites and sponsors.

This strategic collaboration between Cognizant and Florence will leverage the two company’s platforms to allow for the seamless end-to-end exchange of documents from sponsor electronic trial master file (eTMF) systems to the Florence eRegulatory binder through Cognizant Shared Investigator Platform (SIP). As a result, this partnership quickens site activation, lessens site burden, simplifies workflows, and streamlines stakeholder communication. 

  • Cognizant SIP is the only open, collaborative clinical trial technology platform, leveraging one environment across multiple sponsors and operating via common workflows and documents.
  • Florence eBinders eISF assists sites in saving time by reducing paperwork and giving clinical trial sponsors remote access to a vast majority of their study sites.

The strategic collaboration between Cognizant and Florence establishes a way for sponsors to migrate from paper-based binder processes to modern, digital document exchange with automated workflows and e-signature capabilities, enabling sites and sponsors to work together seamlessly on both regulatory and source content.

More than 1.5 lakh users and over 26000 sites across 98 countries utilize Cognizant SIP. It helps sponsors and contracts research organizations to connect with sites across the World and facilitate study participation by multicultural, diverse patient populations, improving therapeutics‘ safety and efficacy.

Florence is used by over 8500 research teams in 34 countries to manage their eISF. It increases compliance and reduces document cycle times by 40 percent during a clinical study with eSignatures, eLogs, source capture, and management solutions, fillable forms, document status alerts, and remote site access for monitoring and source review.

“By partnering with Florence, the leader in digital site workflows, the company solidifies our site-centric focus to enhance the overall clinical trial experience while accelerating study timelines,” said Srinivas Shankar, Global Head of Cognizant Life Sciences.

 Ryan Jones, CEO of Florence, said that this collaboration with Cognizant connects SIP sponsors to the Florence network of digital research-ready sites.

For Latest IT Industry News, Follow us on Google News and Twitter